Metformin Is Associated With Survival Benefit in Cancer Patients With Concurrent Type 2 Diabetes: A Systematic Review and Meta-Analysis
A partir d'une revue systématique de la littérature (20 études, 13 008 participants), cette méta-analyse évalue les effets d'un traitement par metformine sur l'amélioration de la survie des patients atteints de cancer et d'un diabète de type 2
Purpose. Patients with type 2 diabetes have increased cancer risk and cancer-related mortality, which can be reduced by metformin treatment. However, it is unclear whether metformin can also modulate clinical outcomes in patients with cancer and concurrent type 2 diabetes.
Patients and Methods. A meta-analysis of 20 publications that included 13,008 subjects was performed to investigate the association between metformin and overall survival (OS) as well as cancer-specific survival (CSS) in patients with cancer and concurrent type 2 diabetes.
Results. We found that there was a relative survival benefit associated with metformin treatment compared with treatment with other glucose-lowering medications in both OS and CSS (hazard ratio [HR] = 0.66; 95% confidence interval [CI]: 0.55–0.79 and HR = 0.62; 95% CI: 0.46–0.84, respectively). These associations were also observed in subgroups by cancer type and country.
Conclusion. These results suggest that metformin is the drug of choice in the treatment of patients with cancer and concurrent type 2 diabetes.
The Oncologist , résumé, 2013